Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients.

Publication Type:

Journal Article

Source:

Cancer research, Volume 70, Issue 21, p.8388-97 (2010)

Keywords:

2010, Adult, Aged, Aged, 80 and over, Antibodies, Antigens, Polyomavirus Transforming, Carcinoma, Merkel Cell, Case-Control Studies, Center-Authored Paper, Clinical Research Division, DNA, Viral, Female, Human Biology Division, Humans, Immunoenzyme Techniques, Male, Merkel Cells, Middle Aged, Mutagenesis, Site-Directed, Plasmids, Polyomavirus, Polyomavirus Infections, Prognosis, Public Health Sciences Division, Shared Resources, Skin Neoplasms, Specimen Processing Core Facility, Tissue Array Analysis

Abstract:

Merkel cell polyomavirus (MCPyV) is a common infectious agent that is likely involved in the etiology of most Merkel cell carcinomas (MCC). Serum antibodies recognizing the MCPyV capsid protein VP1 are detectable at high titer in nearly all MCC patients and remain stable over time. Although antibodies to the viral capsid indicate prior MCPyV infection, they provide limited clinical insight into MCC because they are also detected in more than half of the general population. We investigated whether antibodies recognizing MCPyV large and small tumor-associated antigens (T-Ag) would be more specifically associated with MCC. Among 530 population control subjects, these antibodies were present in only 0.9% and were of low titer. In contrast, among 205 MCC cases, 40.5% had serum IgG antibodies that recognize a portion of T-Ag shared between small and large T-Ags. Among cases, titers of T-Ag antibodies fell rapidly (∼8-fold per year) in patients whose cancer did not recur, whereas they rose rapidly in those with progressive disease. Importantly, in several patients who developed metastases, the rise in T-Ag titer preceded clinical detection of disease spread. These results suggest that antibodies recognizing T-Ag are relatively specifically associated with MCC, do not effectively protect against disease progression, and may serve as a clinically useful indicator of disease status.